Feature

Article

Pharmaceutical Technology

Pharmaceutical Technology, November 2023
Volume47
Issue 11
Pages: 10

Capitalizing on Success

Industry investments indicate increasing trust in the newest modalities, including mRNA approaches.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

As of mid-October 2023, there were 9342 clinical trial studies targeting COVID-19 (1). This is alongside 12,086 patents that relate to COVID-19 (2). Messenger RNA (mRNA) clinical trials, however, stand at only 483, with 112 related patents. mRNA was the talk of the industry during October 2023, as Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their work in mRNA vaccines against COVID-19.
In an interview with Pharmaceutical Technology®, Laks Pernenkil, Principal and Practice Leader, US Life Sciences, Deloitte, pointed to “an emphasis coming out of the pandemic on supply resilience … with all the ups and downs around the supply of raw materials, there has been significant focus on ensuring patients are not affected by supply shortages, part of the anxiety has manifested around inflation [rising costs] of raw materials.” Pernenkil also drew attention to increased digitalization as improving process design, supply performance, and eventually, profits (3).
At the other end of the spectrum, discovering new types of drugs and therapies, the top five pharmaceutical companies’ investments in R&D in 2022 were Roche with $14.78 Billion, J&J $14.14 billion, Pfizer $12.38 billion, Merck $11.84, and BMS $10.02 billion, ranging between 15% to 30% of income (4). Such investment speaks of self-confidence and perhaps aligns with increasing trust in the newest modalities, including mRNA approaches.

References

  1. NIH. https://clinicaltrials.gov. Clinical trials.gov (accessed Oct. 12, 2023).
  2. World Health Organization, WHO’s Covid-19 Response Timeline (accessed Oct. 12, 2023).
  3. Playter, G. The Era of Digital Data in Bio/Pharma Manufacturing. PharmTech.com. Oct. 9, 2023.
  4. Statista. Leading 50 Global Pharmaceutical Companies by Prescription Sales and R&D Spending in 2022. Statista (accessed Oct. 12, 2023).

Article details

Pharmaceutical Technology
Vol. 47, No. 11
November 2023
Page: 10

Citation

When referring to this article, please cite it as Hennessy, M. Capitalizing on Success. Pharmaceutical Technology 2023 47 (11).

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content